Intraindividual comparison of selective arterial vs. venous 68Ga-DOTATOC-PET/CT in patients with gastroenteropancreatic neuroendocrine tumors

TL;DRAbstract

1160 Objectives Therapy with the somatostatin analog DOTATOC labeled with a beta-emitter such as 90Y or 177Lu is accepted for the palliative treatment of unresectable neuroendocrine cancer. However, the optimal route of administration has not been determined. Using PET labeled 68Ga-DOTATOC we compared selective tumoral uptake on PET/CT after arterial or venous administration of the agent in patients with gastroenteropancreatic neuroendocrine tumor. Methods Fifteen patients with neuroendocrine cancer (NET) were examined with 68Ga-DOTATOC PET/CT after intravenous and intraarterial administration within four weeks of each other and without any intervening therapy. Eleven patients had multifocal metastases; 6 were considered to have unresectable primary tumor. The intraarterial catheter was placed in the vessel supplying the main tumor burden. The standard uptake value (SUV)was used to compare intra-tumoral concentrations of 68Ga-DOTATOC. Results Compared with i.v. infusion, the i.a. infus

Chat with Paper

AI Agents for this Paper